ALK-Abelló A/S
ALK-B
Κατάταξη σε μετοχές
#2352
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Τιμή μετοχής
$37.76
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$8.38B
Αλλαγή (1 ημέρα)
-0.08%
Αλλαγή (1 έτος)
14.34%
Χώρα
DK
Εμπόριο ALK-Abelló A/S (ALK-B)
Κατηγορία
Healthcare
Κέρδη για την ALK-Abelló A/S (ALK-B)
Κέρδη τον Jun 2026 TTM: $293.25M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της ALK-Abelló A/S, τα τρέχοντα κέρδη της εταιρείας είναι $293.25M. Το 2023, η εταιρεία παρουσίασε κέρδη $95.80M, αύξηση σε σχέση με των κερδών του 2022 που ήταν $64.34M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την ALK-Abelló A/S από 2004 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $293.25M | 98.85% |
| 2024 | $147.48M | 53.95% |
| 2023 | $95.80M | 48.90% |
| 2022 | $64.34M | 50.79% |
| 2021 | $42.67M | 157.35% |
| 2020 | $16.58M | -456.36% |
| 2019 | $-4.65M | -70.59% |
| 2018 | $-15.82M | -19.54% |
| 2017 | $-19.66M | -128.45% |
| 2016 | $69.12M | 18.58% |
| 2015 | $58.29M | 19.46% |
| 2014 | $48.79M | 154.41% |
| 2013 | $19.18M | -4.03% |
| 2012 | $19.98M | -64.26% |
| 2011 | $55.91M | 50.59% |
| 2010 | $37.12M | 1.19% |
| 2009 | $36.69M | 25.00% |
| 2008 | $29.35M | -35.66% |
| 2007 | $45.62M | 177.96% |
| 2006 | $16.41M | -257.10% |
| 2005 | $-10.45M | -128.29% |
| 2004 | $36.93M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | 1,698.75% |
US
|
|
| $-3.09B | -1,152.67% |
US
|
|
| $-4.02B | -1,469.53% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 565.18% |
NL
|
